NASDAQ:CPRX - Catalyst Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.37 -0.18 (-5.07 %) (As of 05/23/2019 02:55 PM ET)Previous Close$3.55Today's Range$3.33 - $3.5552-Week Range$1.85 - $6.16Volume38,814 shsAverage Volume4.61 million shsMarket Capitalization$346.60 millionP/E RatioN/ADividend YieldN/ABeta2.43 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with New York University, the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc.; and collaboration agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Receive CPRX News and Ratings via Email Sign-up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CPRX Previous Symbol CUSIPN/A CIK1369568 Webhttp://www.catalystpharma.com/ Phone305-420-3200Debt Debt-to-Equity Ratio0.02 Current Ratio6.08 Quick Ratio6.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio30.64 P/E GrowthN/A Sales & Book Value Annual Sales$500,000.00 Price / Sales693.21 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book6.74Profitability EPS (Most Recent Fiscal Year)($0.33) Net Income$-34,000,000.00 Net MarginsN/A Return on Equity-48.84% Return on Assets-43.94%Miscellaneous Employees51 Outstanding Shares102,850,000Market Cap$346.60 million Next Earnings Date8/6/2019 (Estimated) OptionableOptionable Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions What is Catalyst Pharmaceuticals' stock symbol? Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX." How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) posted its quarterly earnings data on Monday, May, 13th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.12. The biopharmaceutical company earned $12.45 million during the quarter, compared to analyst estimates of $2.40 million. During the same quarter in the previous year, the firm posted ($0.06) earnings per share. View Catalyst Pharmaceuticals' Earnings History. When is Catalyst Pharmaceuticals' next earnings date? Catalyst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Catalyst Pharmaceuticals. What price target have analysts set for CPRX? 4 analysts have issued 12 month target prices for Catalyst Pharmaceuticals' shares. Their predictions range from $6.00 to $10.00. On average, they anticipate Catalyst Pharmaceuticals' stock price to reach $8.1250 in the next twelve months. This suggests a possible upside of 141.1% from the stock's current price. View Analyst Price Targets for Catalyst Pharmaceuticals. What is the consensus analysts' recommendation for Catalyst Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalyst Pharmaceuticals. What are Wall Street analysts saying about Catalyst Pharmaceuticals stock? Here are some recent quotes from research analysts about Catalyst Pharmaceuticals stock: 1. According to Zacks Investment Research, "Catalyst reported narrower-than-expected loss and sales beat estimates in the first quarter of 2019. Firdapse is the company’s first approved product. The drug is the first FDA-approved treatment for Lambert-Eaton Myasthenic Syndrome (LEMS) in adults, which was approved in November 2018 and launched in January. The company generated entire first-quarter revenues from Firdapse. Catalyst is also developing Firdapse to treat additional rare neuromuscular diseases. However, all the other candidates in its portfolio are in early stages of development. Thus, the successful development and commercialization of drug candidates are highly crucial for the company. Shares of the company have outperformed the industry year to date." (5/21/2019) 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and PT of $10 per share of CPRX. the FDA approved private company the treatment of LEMS in pts 6 to <17 years of age. This is the first drug approved for pediatric LEMS. However, Catalyst's slighty different salt form of amifampridine, marketed as Firdapse, was the first drug approved for LEMS, but for adults only. We were surprised by this announcement as no clinical studies were conducted in the pediatric population that we are aware of, and the approval relied on studies of the drug in adults with LEMS, including PK data that were then modeled/extrapolated to identify the dosing regimen in pediatric pts."" (5/7/2019) 3. HC Wainwright analysts commented, "We raised our PT to $9 from $6 in view of the additional color on the commercial front. We adjusted the launch cost of and lowered the peak penetration from 25% to 18%." (12/14/2018) Has Catalyst Pharmaceuticals been receiving favorable news coverage? News stories about CPRX stock have been trending somewhat positive this week, according to InfoTrie. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Catalyst Pharmaceuticals earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an effect on the company's share price in the next several days. Who are some of Catalyst Pharmaceuticals' key competitors? Some companies that are related to Catalyst Pharmaceuticals include Innoviva (INVA), Endo International (ENDP), Heron Therapeutics (HRTX), Cambrex (CBM), Esperion Therapeutics (ESPR), Gossamer Bio (GOSS), Opko Health (OPK), Aimmune Therapeutics (AIMT), Apellis Pharmaceuticals (APLS), Phibro Animal Health (PAHC), Corcept Therapeutics (CORT), Epizyme (EPZM), Turning Point Therapeutics (TPTX), Theravance Biopharma (TBPH) and Eidos Therapeutics (EIDX). What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Cognex (CGNX), SLS International (SLS), Verastem (VSTM), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE). Who are Catalyst Pharmaceuticals' key executives? Catalyst Pharmaceuticals' management team includes the folowing people: Mr. Patrick J. McEnany, Co-Founder, Chairman, Pres & CEO (Age 72)Ms. Alicia Grande, VP, Treasurer & CFO (Age 48)Dr. Steven R. Miller, COO & Chief Scientific Officer (Age 57)Mr. Brian Elsbernd, Chief Legal & Compliance Officer (Age 55)Dr. Gary Ingenito, Chief Medical Officer & Head of Regulatory Affairs (Age 63) Who are Catalyst Pharmaceuticals' major shareholders? Catalyst Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.80%), Broadfin Capital LLC (5.69%), Morgan Stanley (2.25%), Opaleye Management Inc. (1.77%), Geode Capital Management LLC (1.12%) and Kennedy Capital Management Inc. (0.97%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Donald A Denkhaus and Patrick J Mcenany. View Institutional Ownership Trends for Catalyst Pharmaceuticals. Which major investors are selling Catalyst Pharmaceuticals stock? CPRX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Broadfin Capital LLC, Knott David M, California State Teachers Retirement System, Wells Fargo & Company MN, California Public Employees Retirement System, Tanaka Capital Management Inc. and Jacobs Levy Equity Management Inc.. View Insider Buying and Selling for Catalyst Pharmaceuticals. Which major investors are buying Catalyst Pharmaceuticals stock? CPRX stock was purchased by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Kennedy Capital Management Inc., EAM Global Investors LLC, Parametric Portfolio Associates LLC, SEI Investments Co, Geode Capital Management LLC, Ibex Investors LLC and State of Wisconsin Investment Board. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, Donald A Denkhaus and Patrick J Mcenany. View Insider Buying and Selling for Catalyst Pharmaceuticals. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Catalyst Pharmaceuticals' stock price today? One share of CPRX stock can currently be purchased for approximately $3.37. How big of a company is Catalyst Pharmaceuticals? Catalyst Pharmaceuticals has a market capitalization of $346.60 million and generates $500,000.00 in revenue each year. The biopharmaceutical company earns $-34,000,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. Catalyst Pharmaceuticals employs 51 workers across the globe. What is Catalyst Pharmaceuticals' official website? The official website for Catalyst Pharmaceuticals is http://www.catalystpharma.com/. How can I contact Catalyst Pharmaceuticals? Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected] MarketBeat Community Rating for Catalyst Pharmaceuticals (NASDAQ CPRX)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 360 (Vote Outperform)Underperform Votes: 196 (Vote Underperform)Total Votes: 556MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: What are popular green investing opportunities? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.